• 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest
• A case report of invasive infantile primary hyperoxaluria type 1 and literature review
• A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran
• A clinical screening algorithm for primary hyperoxaluria type 1 in adults on dialysis
• A Rare Sparkle: A Case of Calcified Kidneys in a Young Infant With Renal Failure
• Bilateral nephrocalcinosis: primary hyperoxaluria involved
• Biochemical and cellular effects of a novel missense mutation of the AGXT gene associated with Primary Hyperoxaluria Type 1
• Bone health in children with primary hyperoxaluria type 1 following liver and kidney transplantation
• Bone marrow aspirate: a diagnostic tool for primary hyperoxaluria type 1
• Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1
• Case series and literature review of primary hyperoxaluria type 1 in Chinese patients
• Characteristics and Graft Outcomes of Kidney Transplant Candidates with Enteric Risk Factors and Elevated Plasma Oxalate Levels
• Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria
• Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I
• Clinical analysis of seven cases of primary hyperoxaluria type 1
• Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study
• Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
• Combined liver-kidney transplantation in pediatric patients
• Comprehensive evaluation of patients with primary hyperoxaluria type 1: A nationwide study
• Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1
• Corrigendum: Primary Hyperoxaluria Type 1 (PH1) Presenting with End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report
• CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1
• Cutaneous Oxalosis Due to Primary Hyperoxaluria
• Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium
• Diagnosis and management of primary hyperoxalurias: best practices
• Diagnostic policies on nephrolithiasis/nephrocalcinosis of possible genetic origin by Italian nephrologists: a survey by the Italian Society of Nephrology with an emphasis on primary hyperoxaluria
• Dialysis in Israeli Children between 1990 and 2020: Trends and International Comparisons
• Distinguishing characteristics of pediatric patients with primary hyperoxaluria type 1 in PEDSnet
• Effect of liver transplantation with primary hyperoxaluria type 1: Five case reports and review of literature
• Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
• Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
• Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
• End Point Considerations for Clinical Trials in Enteric Hyperoxaluria
• ESKD in a Young Patient with Chronic Bilateral Flank Pain
• Estimating health state utilities in primary hyperoxaluria type 1: a valuation study
• Expanding the Genetic Spectrum of <em>AGXT</em> Gene Variants in Egyptian Patients with Primary Hyperoxaluria Type I
• Gene editing: a near future for the treatment of genetic kidney diseases
• Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1
• Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate
• Haemolytic uraemic syndrome
• HOGA1 variants in Chinese patients with primary hyperoxaluria type 3: genetic features and genotype-phenotype relationships
• How We Treat Primary Hyperoxaluria Type 1
• In vivo base editing rescues primary hyperoxaluria type 1 in rats
• Incidence of Kidney Stones After Metabolic and Bariatric Surgery-Data from the Scandinavian Obesity Surgery Registry
• Is Genotype the Major Outcome Parameter of Kidney Failure in Patients With Primary Hyperoxaluria Type 1?
• Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
• Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases
• Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias
• Lessons for the clinical nephrologist: lumasiran as the future cornerstone treatment for patients with primary hyperoxaluria type 1?
• Long-term outcome after combined or sequential liver and kidney transplantation in children with infantile and juvenile primary hyperoxaluria type 1
• Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1
• Lumasiran (Oxlumo): CADTH Reimbursement Recommendation: Indication: For the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients
• Lumasiran (Oxlumo): CADTH Reimbursement Review: Therapeutic area: Primary hyperoxaluria type 1
• Lumasiran (Oxlumo): CADTH Reimbursement Review: Therapeutic area: Primary hyperoxaluria type 1 [Internet]
• Lumasiran for primary hyperoxaluria type 1: What we have learned?
• Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy
• Lumasiran: a potential therapy for the management of primary hyperoxaluria type 1? An editorial
• Lumasiran: A Review in Primary Hyperoxaluria Type 1
• Modified by the Innovative Drugs and Strategies-Pattern of Selected Indications for Pediatric Liver Transplantation
• Monogenic urinary lithiasis in Tunisian children: 25 years' experience of a referral center
• Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1
• Multimodal Imaging of Severe Oxalate Retinopathy in a 20-Month-Old Boy
• Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1
• Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1
• Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1
• Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3
• Nephrocalcinosis can disappear in infants receiving early lumasiran therapy
• Ophthalmic Sequelae of Late-Stage Primary Hyperoxaluria Type 1
• Pediatric combined living donor liver and kidney transplantation for primary hyperoxaluria type 2
• PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2
• Plasma oxalate and glycolate concentrations in dialysis patients with and without primary hyperoxaluria type 1
• Preemptive liver transplant in two patients with primary hyperoxaluria type 1: Clinical significance of nephrolithiasis and nephrocalcinosis
• Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome
• Primary hyperoxaluria type 1-a rare hereditary metabolic disorder as cause of livedo racemosa
• Primary hyperoxaluria type 1: Clinical, genetic, and evolutionary characteristics in Tunisian children
• Primary Hyperoxaluria Type 1: Clinical, Paraclinical, and Evolutionary Aspects in Adults from One Nephrology Center
• Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study
• Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials
• Recurrent symptomatic urolithiasis in a patient with cystic fibrosis
• Reduced Electroretinogram Responses in Morphologically Normal Retina in Patients with Primary Hyperoxaluria Type 1
• Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts
• Retraction: Molecular Diagnosis of Primary Hyperoxaluria Type 1 and Distal Renal Tubular Acidosis in Moroccan Patients With Nephrolithiasis and/or Nephrocalcinosis
• RNA therapeutics for disorders of excretory system
• RNA therapeutics for metabolic disorders
• Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches
• Simple, fast and inexpensive quantification of glycolate in the urine of patients with primary hyperoxaluria type 1
• Small Interfering RNA (siRNA) Therapy
• Small Interfering RNA (siRNA) Therapy
• Small Interfering RNA (siRNA)-Based Therapy
• Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review
• Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1
• Successful pregnancy in a hemodialysis patient with primary hyperoxaluria type 1
• Synthesis and <em>h</em>LDH Inhibitory Activity of Analogues to Natural Products with 2,8-Dioxabicyclo[3.3.1]nonane Scaffold
• The appearance of oxalate crystals in a kidney biopsy is no proof of post-transplant oxalate nephropathy in primary hyperoxaluria type 1
• The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria
• The real world experience of pediatric primary hyperoxaluria patients in the PEDSnet clinical research network
• Therapeutic siRNA: State-of-the-Art and Future Perspectives
• Unusual cause of cerebral calcifications in an 8-year-old girl
• Unveiling atypical diagnoses: when whole-genome analysis performed for refractory infantile hypomagnesemia reveals primary hyperoxaluria
• Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases